Proteases and bone remodelling.

[1]  H. Ryoo,et al.  Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross‐talking with RANK signaling , 2008, Journal of cellular physiology.

[2]  S. Komarova,et al.  Osteoclast precursors acquire sensitivity to breast cancer derived factors early in differentiation. , 2008, Bone.

[3]  D. Heymann,et al.  Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3. , 2008, Endocrinology.

[4]  Michael C. Ostrowski,et al.  PU.1 and NFATc1 mediate osteoclastic induction of the mouse β3 integrin promoter , 2008, Journal of cellular physiology.

[5]  T. Kita,et al.  Ectodomain shedding of TNF-alpha is enhanced by nardilysin via activation of ADAM proteases. , 2008, Biochemical and biophysical research communications.

[6]  Y. Konttinen,et al.  Involvement of a disintegrin and a metalloproteinase 8 (ADAM8) in osteoclastogenesis and pathological bone destruction , 2008, Annals of the rheumatic diseases.

[7]  T. Wilson,et al.  Proteases as modulators of tumor-stromal interaction: primary tumors to bone metastases. , 2008, Biochimica et biophysica acta.

[8]  Paul N. Span,et al.  Distinct Functions of Natural ADAM-15 Cytoplasmic Domain Variants in Human Mammary Carcinoma , 2008, Molecular Cancer Research.

[9]  M. Day,et al.  ADAM15 supports prostate cancer metastasis by modulating tumor cell-endothelial cell interaction. , 2008, Cancer research.

[10]  J. Foidart,et al.  Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. , 2008, Biochimie.

[11]  A. Krieg,et al.  The Toll of Cathepsin K Deficiency , 2008, Science.

[12]  K. Miyazono,et al.  Cathepsin K-Dependent Toll-Like Receptor 9 Signaling Revealed in Experimental Arthritis , 2008, Science.

[13]  B. Fuchs,et al.  Cathepsins and osteosarcoma: Expression analysis identifies cathepsin K as an indicator of metastasis , 2008, Molecular carcinogenesis.

[14]  Z. Bar‐Shavit.  Taking a Toll on the bones: Regulation of bone metabolism by innate immune regulators , 2008, Autoimmunity.

[15]  T. Shiomi,et al.  Expression of ADAMTS4 (aggrecanase‐1) in human osteoarthritic cartilage , 2007, Pathology international.

[16]  C. López-Otín,et al.  The ADAMTS12 metalloproteinase exhibits anti-tumorigenic properties through modulation of the Ras-dependent ERK signalling pathway , 2007, Journal of Cell Science.

[17]  V. Castronovo,et al.  A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. , 2007, Cancer research.

[18]  M. Wendel,et al.  ADAMTS-1 increases the three-dimensional growth of osteoblasts through type I collagen processing. , 2007, Bone.

[19]  J. Enghild,et al.  Proteolytic Activities of Human ADAMTS-5 , 2007, Journal of Biological Chemistry.

[20]  R. Baron,et al.  Tumor αvβ3 Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases , 2007 .

[21]  N. Suzuki,et al.  Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells. , 2007, Life sciences.

[22]  M. Padrines,et al.  Key roles of the OPG–RANK–RANKL system in bone oncology , 2007, Expert review of anticancer therapy.

[23]  D. Griggs,et al.  Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. , 2007, Arthritis and rheumatism.

[24]  Y. Kadono,et al.  Negative Regulation of Osteoclastogenesis by Ectodomain Shedding of Receptor Activator of NF-κB Ligand* , 2006, Journal of Biological Chemistry.

[25]  N. Brünner,et al.  TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis , 2006, British Journal of Cancer.

[26]  D. Sheppard,et al.  α9β1: A Novel Osteoclast Integrin That Regulates Osteoclast Formation and Function , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  Y. Itoh,et al.  MT1‐MMP: A key regulator of cell migration in tissue , 2006, IUBMB life.

[28]  O. Ishibashi,et al.  MMP-9 antisense oligodeoxynucleotide exerts an inhibitory effect on osteoclastic bone resorption by suppressing cell migration. , 2006, Life sciences.

[29]  Frédéric Blanchard,et al.  Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: Role in the interactions with receptor activator of nuclear factor κB ligand (RANKL) and RANK , 2006 .

[30]  P. Croucher,et al.  ADAM-9 (mdc-9/meltrin-γ), a member of the a disintegrin and metalloproteinase family, regulates myeloma cell induced interleukin-6 production in osteoblasts by direct interaction with the αvβ5-integrin , 2006 .

[31]  S. Ricard-Blum,et al.  Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. , 2006, Biochemical and biophysical research communications.

[32]  S. Mohan,et al.  Regulation of insulin-like growth factor binding protein-5, four and a half lim-2, and a disintegrin and metalloprotease-9 expression in osteoblasts. , 2006, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[33]  T. Shiomi,et al.  Pericellular activation of proMMP-7 (promatrilysin-1) through interaction with CD151 , 2005, Laboratory Investigation.

[34]  Judith M. White,et al.  Selective modulation of integrin-mediated cell migration by distinct ADAM family members. , 2005, Molecular biology of the cell.

[35]  O. Fodstad,et al.  Matrix metalloproteinases participate in osteosarcoma invasion. , 2005, The Journal of surgical research.

[36]  M. Pelto-huikko,et al.  Shedding light on ADAM metalloproteinases. , 2005, Trends in biochemical sciences.

[37]  P. Kronqvist,et al.  A role for ADAM12 in breast tumor progression and stromal cell apoptosis. , 2005, Cancer research.

[38]  N. Nonomura,et al.  Prostate cancer mediates osteoclastogenesis through two different pathways. , 2005, Cancer letters.

[39]  C. Little,et al.  ADAMTS-1-knockout mice do not exhibit abnormalities in aggrecan turnover in vitro or in vivo. , 2005, Arthritis and rheumatism.

[40]  Tomoyuki Shirai,et al.  MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. , 2005, Cancer cell.

[41]  A. Fourie,et al.  ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro , 2005, Nature.

[42]  W. Hornebeck,et al.  Beneficial and detrimental influences of tissue inhibitor of metalloproteinase-1 (TIMP-1) in tumor progression. , 2005, Biochimie.

[43]  M. Wendel,et al.  The hyalectan degrading ADAMTS-1 enzyme is expressed by osteoblasts and up-regulated at regions of new bone formation. , 2005, Bone.

[44]  S. Théoleyre,et al.  The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. , 2004, Cytokine & growth factor reviews.

[45]  Y. Nogi,et al.  Essential Role of p38 Mitogen-activated Protein Kinase in Cathepsin K Gene Expression during Osteoclastogenesis through Association of NFATc1 and PU.1* , 2004, Journal of Biological Chemistry.

[46]  J. Foidart,et al.  Membrane associated proteases and their inhibitors in tumour angiogenesis , 2004, Journal of Clinical Pathology.

[47]  L. Mir,et al.  Evidence of Antiangiogenic and Antimetastatic Activities of the Recombinant Disintegrin Domain of Metargidin , 2004, Cancer Research.

[48]  S. Théoleyre,et al.  Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities. , 2004, Experimental cell research.

[49]  C Dunstan,et al.  Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of nuclear factor kappaB ligand and MAPK. , 2004, Biochimica et biophysica acta.

[50]  P. Picci,et al.  Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcomaFindings in 42 patients followed for 1–16 years , 2004, Acta orthopaedica Scandinavica.

[51]  Feras Hawari,et al.  Shedding of the Type II IL-1 Decoy Receptor Requires a Multifunctional Aminopeptidase, Aminopeptidase Regulator of TNF Receptor Type 1 Shedding , 2003, The Journal of Immunology.

[52]  E. Jimi,et al.  Receptor Activator of NF-κB Ligand Stimulates Recruitment of SHP-1 to the Complex Containing TNFR-Associated Factor 6 That Regulates Osteoclastogenesis1 , 2003, The Journal of Immunology.

[53]  J. White.  ADAMs: modulators of cell-cell and cell-matrix interactions. , 2003, Current opinion in cell biology.

[54]  J. Krupa,et al.  Use of anti-neoepitope antibodies for the analysis of degradative events in cartilage and the molecular basis for neoepitope specificity. , 2003, Biochemical Society symposium.

[55]  K. Brew,et al.  Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors. , 2003, Biochemical Society symposium.

[56]  J. Delaissé,et al.  Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities , 2003, Microscopy research and technique.

[57]  K. Horiuchi,et al.  Potential Role for ADAM15 in Pathological Neovascularization in Mice , 2003, Molecular and Cellular Biology.

[58]  J. Wilhelm,et al.  Increased expression of disintegrin‐metalloproteinases ADAM‐15 and ADAM‐9 following upregulation of integrins α5β1 and αvβ3 in atherosclerosis , 2003 .

[59]  M. Iruela-Arispe,et al.  ADAMTS1/METH1 Inhibits Endothelial Cell Proliferation by Direct Binding and Sequestration of VEGF165* , 2003, Journal of Biological Chemistry.

[60]  B. Gelb,et al.  Collagenase Activity of Cathepsin K Depends on Complex Formation with Chondroitin Sulfate* , 2002, The Journal of Biological Chemistry.

[61]  R. Grimer,et al.  Stage-IIB osteosarcomas around the knee. A study of MMP-9 in surviving tumour cells. , 2002, The Journal of bone and joint surgery. British volume.

[62]  M. Kumegawa,et al.  Tissue Inhibitor of Metalloproteinases 1 and 2 Directly Stimulate the Bone‐Resorbing Activity of Isolated Mature Osteoclasts , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[63]  M. Zaidi,et al.  Cathepsin K, Osteoclastic Resorption, and Osteoporosis Therapy , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[64]  E. Vuorio,et al.  Accelerated Turnover of Metaphyseal Trabecular Bone in Mice Overexpressing Cathepsin K , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[65]  D. Goltzman.  Osteolysis and cancer. , 2001, The Journal of clinical investigation.

[66]  D. Fisher,et al.  Linking osteopetrosis and pycnodysostosis: Regulation of cathepsin K expression by the microphthalmia transcription factor family , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[67]  V. Speirs.  Matrix metalloproteinases and angiogenesis , 2000, Breast Cancer Research.

[68]  L. Lum,et al.  Evidence for a Role of a Tumor Necrosis Factor-α (TNF-α)-converting Enzyme-like Protease in Shedding of TRANCE, a TNF Family Member Involved in Osteoclastogenesis and Dendritic Cell Survival* , 1999, Journal of Biological Chemistry.

[69]  K. Tatsumi,et al.  Inhibition of Spontaneous Rat Osteosarcoma Lung Metastasis by 3S‐[4‐(Nhydroxyamino)‐2R‐isobutylsuccinyl]amino‐1‐methoxy‐3,4‐dihydrocarbostyril, a Novel Matrix Metalloproteinase Inhibitor , 1999, Japanese journal of cancer research : Gann.

[70]  P. Henriet,et al.  Tissue inhibitors of metalloproteinases (TEMP) in invasion and proliferation , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[71]  D. Lacey,et al.  Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors , 1999, Journal of cellular biochemistry.

[72]  Y. Takada,et al.  Specific Interaction of the Recombinant Disintegrin-like Domain of MDC-15 (Metargidin, ADAM-15) with Integrin αvβ3* , 1998, The Journal of Biological Chemistry.

[73]  G. Bilbe,et al.  Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry. , 1997, Bone.

[74]  B. Gelb,et al.  Pycnodysostosis, a Lysosomal Disease Caused by Cathepsin K Deficiency , 1996, Science.

[75]  R. Jaenisch,et al.  A targeted mutation at the known collagenase cleavage site in mouse type I collagen impairs tissue remodeling , 1995, The Journal of cell biology.

[76]  B. Samuelsson,et al.  Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts. , 2008, Bone.

[77]  S. Reddy,et al.  RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation. , 2007, Experimental cell research.

[78]  R. Baron,et al.  Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. , 2007, Cancer research.

[79]  Gillian Murphy,et al.  Structure and function of matrix metalloproteinases and TIMPs. , 2006, Cardiovascular research.

[80]  P. Croucher,et al.  ADAM-9 (MDC-9/meltrin-gamma), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the alpha(v)beta5 integrin. , 2006, Blood.

[81]  V. Salih,et al.  Bone morphogenetic protein receptors and bone morphogenetic protein signaling are controlled by tumor necrosis factor-alpha in human bone cells. , 2006, The international journal of biochemistry & cell biology.

[82]  N. Ishiguro,et al.  Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma. , 2006, International journal of oncology.

[83]  J. Wilhelm,et al.  Increased expression of disintegrin-metalloproteinases ADAM-15 and ADAM-9 following upregulation of integrins alpha5beta1 and alphavbeta3 in atherosclerosis. , 2003, Journal of cellular biochemistry.

[84]  R. Black,et al.  Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. , 2000, The Journal of biological chemistry.

[85]  L. Lum,et al.  Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. , 1999, The Journal of biological chemistry.

[86]  Y. Takada,et al.  Specific interaction of the recombinant disintegrin-like domain of MDC-15 (metargidin, ADAM-15) with integrin alphavbeta3. , 1998, The Journal of biological chemistry.